Lantheus (LNTH)
(Delayed Data from NSDQ)
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 5:52 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 5:52 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know
by Zacks Equity Research
Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Lantheus Holdings (LNTH) closed at $89.21, marking a -1.7% move from the previous day.
Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Lantheus Holdings (LNTH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Lantheus Holdings (LNTH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Lantheus Holdings (LNTH) closed at $83.83, marking a +0.5% move from the previous day.
Is It Worth Investing in Lantheus Holdings (LNTH) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Lantheus Holdings (LNTH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Lantheus Holdings (LNTH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Lantheus Holdings (LNTH) closed at $82.40, marking a +1.22% move from the previous day.
Lantheus Holdings (LNTH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) closed the most recent trading day at $81.41, moving -1.26% from the previous trading session.
Lantheus and GlobalFoundries have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Lantheus and GlobalFoundries are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: Lantheus (LNTH)
by Kevin Cook
Medical diagnostics leader in prostate cancer is driving 34% sales and 32% EPS growth
Teleflex's (TFX) Urolift Global Expansion Aids Amid Cost Woes
by Zacks Equity Research
Teleflex's (TFX) vascular and interventional access product portfolios witness accelerated growth following the $976-million acquisition of Vascular Solutions.
Labcorp (LH) Announces Completion of the Fortrea Spin-off
by Zacks Equity Research
Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.
Acadia Healthcare (ACHC) Inks JV to Better Serve New Hampshire
by Zacks Equity Research
Acadia Healthcare (ACHC) enters into a JV with New Hampshire-based SolutionHealth to build a behavioral health facility and address the dire need for advanced behavioral health services across the state.
Bruker (BRKR) Launches the SciY Platform of Software Solutions
by Zacks Equity Research
Bruker's (BRKR) SciY platform provides many digital end-to-end solutions for life science research and development, manufacturing automation and QC.
Lantheus Holdings (LNTH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Lantheus Holdings (LNTH) closed at $83.92, marking a +1.17% move from the previous day.
Myriad Genetics (MYGN) Test Volume Rises Amid Margin Woe
by Zacks Equity Research
Myriad Genetics' (MYGN) collaboration with medical imaging provider, SimonMeD, is expected to advance precision medicine with a new hereditary cancer assessment program.
Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems
by Zacks Equity Research
Abbott (ABT) and ADA are going to offer personalized, therapeutic nutrition for diabetes people using CGM systems.
Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) closed at $82.95 in the latest trading session, marking a -1.88% move from the prior day.
BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
by Zacks Equity Research
The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.
OrthoPediatrics (KIDS) Unveils GIRO for Pediatric Orthopedics
by Zacks Equity Research
The GIRO Growth Modulation System by OrthoPediatrics (KIDS) introduces a tether device designed specifically for pediatric patients.
Integra (IART) Completes Enrollment in the DuraSorb IDE Study
by Zacks Equity Research
Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.
3 Top-Ranked Mid-Caps With Big Growth
by Derek Lewis
Mid-caps provide a nice blend of growth potential paired with a more established nature, undoubtedly a solid pairing. Is it time for investors to take a closer look at these three?
Bruker (BRKR) Introduces the D6 PHASER Benchtop XRD Platform
by Zacks Equity Research
Bruker's (BRKR) new D6 PHASER platform is to be used for material analysis and advanced research.
Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind
by Zacks Equity Research
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Investors Heavily Search Lantheus Holdings, Inc. (LNTH): Here is What You Need to Know
by Zacks Equity Research
Lantheus Holdings (LNTH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organigram (OGI) Grows in Cannabis Space With SHRED X Heavies
by Zacks Equity Research
Organigram's (OGI) SHRED X Heavies is not only the first infused pre-roll in the SHRED product portfolio but also joins a lineup of value-driven, convenient and bold-flavored offerings.